India, Russia and CIS countries
Valparin Chrono by Sanofi India
Valprol CR by Intas Pharmaceutical (India)
Encorate Chrono by Sun Pharmaceutical (India)
Serven Chrono by Leeven APL Biotech (India)

Brand names of valproate semisodium
Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
Canada – Epival by Abbott Laboratories
Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics
India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
Germany – Ergenyl Chrono by Sanofi-Aventis and generics
Chile – Valcote and Valcote ER by Abbott Laboratories
France and other European countries — Depakote
Peru – Divalprax by AC Farma Laboratories
China – Diprate OD

References
External links
"Valproic acid". Drug Information Portal. U.S. National Library of Medicine. "Valproate sodium". Drug Information Portal. U.S. National Library of Medicine. "Divalproex sodium". Drug Information Portal. U.S. National Library of Medicine.
A full endoscopic examination of the larynx, trachea, and esophagus is often performed at the time of biopsy.For small glottic tumours further imaging may be unnecessary. In most cases, tumour staging is completed by scanning the head and neck region to assess the local extent of the tumour and any pathologically enlarged cervical lymph nodes. The final management plan will depend on the site, stage (tumour size, nodal spread, distant metastasis), and histological type. The overall health and wishes of the patient must also be taken into account. A prognostic multigene classifier has been shown to be potentially useful for the distinction of laryngeal cancer of low or high risk of recurrence and might influence the treatment choice in future. Staging
Laryngeal tumours are classified according to the guidelines set by academic organisations such as the National Comprehensive Cancer Network (NCCN) . Overall classification, also known as "staging", can help predict treatment options for patients. Staging consists of three separate evaluations. The first is of the tumour/cancer itself ("T"). The second is the extent to which adjacent lymph nodes are involved in the tumour/cancers spread ("N"). The third is the presence or absence of any distant metastases ("M). The specific “staging” criteria for laryngeal cancer, as utilised in the NCCN’s 2019 Guidelines for Head and Neck Cancers, are:

T
TX: Unable to assess
Tis: Carcinoma in situ

Supraglottis
T1: Tumour present in only one subsite of the supraglottis. Vocal cords have normal mobility. T2: Tumour invades mucosa. There is no fixation of the larynx.